Towards Healthcare
HIV PrEP Market Analysis from 2025 to 2034

HIV PrEP Market Shaped by New Therapies and Global Funding

The HIV PrEP market is expanding due to its growing approvals as well as rising long-acting injectable PrEP innovations. North America led the market due to the early adoption of the HIV PrEP.

  • Insight Code: 6233
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

FAQ's

the HIV PrEP market is expected to soar, driven by technological advancements and changing consumer needs. Explore trends, insights, and future potential.

North America is currently leading the HIV PrEP market due to the early adoption of HIV PrEP.

Some key players include Gilead Sciences, ViiV Healthcare, Janssen/Johnson & Johnson, and Viatris/Mylan.

The HIV PrEP products include daily oral antivirals, on-demand oral regimens, long-acting injectables, topical/vaginal rings, implants, as well as experimental biologics (e.g., broadly neutralizing antibodies, bNAbs).

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.